Proteostasis Therapeutics Inc. (NASDAQ:PTI) and Moleculin Biotech Inc. (NASDAQ:MBRX) are two firms in the Biotechnology that compete against each other. Below is a comparison of their profitability, analyst recommendations, risk, dividends, institutional ownership, earnings and valuation.

Earnings & Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Proteostasis Therapeutics Inc.	2.84M	75.12	61.83M	-1.76	0.00
Moleculin Biotech Inc.	N/A	0.00	11.88M	-0.51	0.00

In table 1 we can see Proteostasis Therapeutics Inc. and Moleculin Biotech Inc.’s top-line revenue, earnings per share and valuation.

Profitability

Table 2 demonstrates the return on equity, net margins and return on assets of Proteostasis Therapeutics Inc. and Moleculin Biotech Inc.

	Net Margins	Return on Equity	Return on Assets
Proteostasis Therapeutics Inc.	-2,177.11%	-104.1%	-76.7%
Moleculin Biotech Inc.	0.00%	0%	0%

Liquidity

The current Quick Ratio of Proteostasis Therapeutics Inc. is 4.2 while its Current Ratio is 4.2. Meanwhile, Moleculin Biotech Inc. has a Current Ratio of 2.1 while its Quick Ratio is 2.1. Proteostasis Therapeutics Inc. is better positioned to pay off its short-term and long-term debts than Moleculin Biotech Inc.

Institutional & Insider Ownership

Roughly 82.9% of Proteostasis Therapeutics Inc. shares are held by institutional investors while 8% of Moleculin Biotech Inc. are owned by institutional investors. Proteostasis Therapeutics Inc.’s share held by insiders are 0.9%. Comparatively, Moleculin Biotech Inc. has 24.24% of it’s share held by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Proteostasis Therapeutics Inc.	9.31%	47.68%	-18.17%	75.59%	43.41%	37.65%
Moleculin Biotech Inc.	-5.71%	-1.49%	-1.49%	-24.14%	-30.16%	26.92%

For the past year Proteostasis Therapeutics Inc. has stronger performance than Moleculin Biotech Inc.

Summary

On 5 of the 9 factors Moleculin Biotech Inc. beats Proteostasis Therapeutics Inc.

Proteostasis Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics that treat diseases caused by dysfunctional protein processing, such as cystic fibrosis. Its lead product candidate is PTI-428, an orally bioavailable cystic fibrosis transmembrane conductance regulator modulator belonging to the amplifier class that is in Phase-I studies. The company is also developing PTI-801, a corrector molecule; PTI-808, a potentiator molecule; and unfolded protein response (UPR) modulators that are in preclinical development. It has collaboration with Astellas Pharma, Inc. to research and identify therapies targeting the Unfolded Protein Response (UPR) pathway. The company was formerly known as Proteoguard, Inc. and changed its name to Proteostasis Therapeutics, Inc. in September 2007. Proteostasis Therapeutics, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts.

Moleculin Biotech, Inc., a preclinical-stage pharmaceutical company, focuses on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia. The company also develops other drugs, including WP1066 Portfolio that focuses on the modulation of regulatory transcription factors involved in the progression of cancer; and WP1122 Portfolio, a suite of molecules targeting the metabolic processes involved in cancer and glioblastoma. The company has an agreement with Mayo Clinic to enable additional research on its WP1066 molecule for the possible treatment of a rare form of pediatric brain tumor. It also has a strategic collaboration with the University of Bergen to develop immune stimulation drug, as well as to expand research on inhibition of brain metastasis by MoleculinÂ’s pre-clinical drug WP1066. Moleculin Biotech, Inc. was founded in 2015 and is headquartered in Houston, Texas.